surmount-1 trial tirzepatide obesity without diabetes 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but diabetes. Researchers Tirzepatide after intensive lifestyle intervention

[28] Sweeting A, Hannah W, Backman H, et al

Electrolyte interactions with other supplements and medications If you are taking other supplements or medications alongside your GLP-1, electrolyte timing and dosing may need adjustment

G.LigiD.OrlandiC.GalluzziL.et al (2016)

Hazama S, Nakamura Y, Takenouchi H, Suzuki N, Tsunedomi R, Inoue Y, et al

Benefits of BPC-157 BPC-157 offers a wide range of benefits, making it an appealing option for both those recovering from injuries and individuals looking to optimize their overall health

2 In approximately 20% of patients, MASLD can progress to metabolic dysfunction-associated steatohepatitis (MASH), characterised by inflammation and ballooning degeneration of hepatocytes, which can progress to cirrhosis and hepatocellular carcinoma (HCC)